BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
June 07 2018 - 8:00AM
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage
biopharmaceutical development company utilizing novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology, today announced the appointment
of Dr. Vincent J. O’Neill as Senior Vice President and Chief
Medical Officer of BTI. Dr. O’Neill has served as Chief
Medical Officer of BTI, on a consulting basis, since July 2017. He
will continue to be responsible for the clinical strategy and
development of BTI’s pipeline assets.
Dr. Vimal Mehta, Founder and Chief Executive
Officer of BTI, commented, “We are excited to have Dr. O’Neill on
the BTI team at this time when we are executing on our pipeline and
moving towards clinical data. During his tenure thus far at BTI,
Vince made a number of noteworthy contributions to BTI. He played a
particularly important role in the success of our recent initial
public offering, initiating our first-in-human clinical trial of
BXCL501 and laying the foundation for clinical development of
BXCL701. Vince has a wealth of experience in the biopharma
landscape, particularly his clinical experience at Genentech. This
coupled with his significant expertise in therapeutic development
will play a crucial role in implementing and advancing BTI’s
pipeline programs through clinical development and
commercialization."
Dr. O'Neill has over 16 years of therapeutic and
diagnostic product development experience. He has held senior
leadership roles at global pharmaceutical companies such as
Genentech, Sanofi and GlaxoSmithKline. Prior to joining the
Company, Dr. O’Neill served as the Senior Vice President and Chief
Medical Officer at Mirna Therapeutics, where he was responsible for
clinical development and medical affairs. At Genentech and
GlaxoSmithKline (“GSK”), he oversaw the clinical and biomarker
development programs for multiple oncology therapeutic assets. He
was instrumental in the expanded approvals of Genentech's oncology
therapeutics, Avastin® and Tarceva®. At GSK, he managed the signal
transduction discovery unit and led the first IND application and
clinical trial of MEK inhibitor MEKINIST®.
Dr. O’Neill received his medical degree and B.Sc.
in molecular pathology from the University of Glasgow. He has
authored several peer-reviewed publications and conference
presentations. Dr. O’Neill is also a member of the Royal College of
Physicians.
“This role offers me a great opportunity to be a
part of a team that is developing drugs that address major unmet
medical needs,” said Dr. O’Neill. “BTI is at a transformative time
of clinical development and the opportunity to grow our pipeline. I
believe that BTI has the potential to be at the forefront of
developing innovative therapies in neuroscience and
immuno-oncology. I am looking forward to working closely with the
entire team to bring novel therapies to the market.”
About BioXcel Therapeutics,
Inc.:BioXcel Therapeutics, Inc. is a clinical stage
biopharmaceutical company focused on drug development that utilizes
novel artificial intelligence to identify the next wave of
medicines across neuroscience and immuno-oncology. The company's
drug re-innovation approach leverages existing approved drugs
and/or clinically validated product candidates together with big
data and proprietary machine learning algorithms to identify new
therapeutic indices. The company's two most advanced clinical
development programs are BXCL501, a sublingual thin film
formulation designed for acute treatment of agitation resulting
from neurological and psychiatric disorders, and BXCL701, an
immuno-oncology agent designed for treatment of a rare form of
prostate cancer and for treatment of pancreatic cancer.
Contact Information:The Ruth
GroupLee Roth/ Janhavi Mohite646-536-7012/
7026
lroth@theruthgroup.com/ jmohite@theruthgroup.com
Forward-Looking Statements:This
press release includes “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements that relate to the advancement and
development of BXCL501 and BXCL701, the commencement of clinical
trials, the availability of data from clinical trials and other
information that is not historical information. When used herein,
words such as “anticipate”, “being”, “will”, “plan”, “may”,
“continue”, and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon BioXcel’s current expectations and various
assumptions. BioXcel believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
BioXcel may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation, market
conditions and the factors described under the caption “Risk
Factors” in BioXcel’s prospectus dated March 7, 2018, and BioXcel’s
other filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as BioXcel’s current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. BioXcel
cannot guarantee future results, events, levels of activity,
performance or achievements. BioXcel does not undertake and
specifically declines any obligation to update, republish, or
revise any forward-looking statements to reflect new information,
future events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by law.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024